These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3365272

  • 1. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
    [Abstract] [Full Text] [Related]

  • 2. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1989 Apr; 39(4):534-8. PubMed ID: 2665759
    [Abstract] [Full Text] [Related]

  • 3. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F, Jang IK, Collen D.
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [Abstract] [Full Text] [Related]

  • 4. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 5. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov 03; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 6. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov 03; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV, Frank JD, Craft TJ, Sundboom JL, Smith GF.
    J Pharmacol Exp Ther; 1992 Jan 03; 260(1):64-70. PubMed ID: 1731052
    [Abstract] [Full Text] [Related]

  • 12. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR.
    J Cardiovasc Pharmacol; 1994 Feb 03; 23(2):203-11. PubMed ID: 7511748
    [Abstract] [Full Text] [Related]

  • 13. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR.
    J Pharmacol Exp Ther; 2003 Aug 03; 306(2):616-23. PubMed ID: 12734394
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of recombinant-derived human superoxide dismutase on porcine left ventricular contractility after normothermic global myocardial ischemia and hypothermic cardioplegic arrest.
    Dworkin GH, Abd-Elfattah AS, Yeh T, Wechsler AS.
    Circulation; 1990 Nov 03; 82(5 Suppl):IV359-66. PubMed ID: 2225428
    [Abstract] [Full Text] [Related]

  • 15. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y, Umemura K, Takiguchi Y, Uematsu T, Nakashima M.
    Blood Coagul Fibrinolysis; 1993 Aug 03; 4(4):569-75. PubMed ID: 7692999
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fibrin-specific thrombolytic agents.
    Collen D.
    Ann Biol Clin (Paris); 1988 Aug 03; 46(3):195-200. PubMed ID: 3044205
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.